Global SARS-CoV-2 seroprevalence: a systematic review and meta-analysis of standardized population-based studies from Jan 2020-May 2022

Simple item page
dc.contributor.authorKolawole, Olatunji
dc.contributor.authorBergeri, Isabel
dc.contributor.authorWhelan, Mairead
dc.contributor.authorWare, Harriet
dc.contributor.authorSubissi, Lorenzo
dc.contributor.authorNardone, Anthony
dc.contributor.authorLewis, Hannah
dc.contributor.authorLi, Zihan
dc.contributor.authorMa, Xiaomeng
dc.contributor.authorValenciano, Marta
dc.contributor.authorCheng, Brianna
dc.contributor.authorAl Ariqi, Lubna
dc.contributor.authorRashidian, Arash
dc.contributor.authorOkeibunnor, Joseph
dc.contributor.authorVan Kerkhove, Maria
dc.contributor.authorUnity Studies Collaborator Group
dc.contributor.authorand more
dc.date.accessioned2023-06-30T10:07:01Z
dc.date.available2023-06-30T10:07:01Z
dc.date.issued2022-11-10
dc.description.abstractBackground Our understanding of the global scale of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection remains incomplete: Routine surveillance data underestimate infection and cannot infer on population immunity; there is a predominance of asymptomatic infections, and uneven access to diagnostics. We meta-analyzed SARS-CoV-2 seroprevalence studies, standardized to those described in the World Health Organization’s Unity protocol (WHO Unity) for general population seroepidemiological studies, to estimate the extent of population infection and seropositivity to the virus 2 years into the pandemic. Methods and findings We conducted a systematic review and meta-analysis, searching MEDLINE, Embase, Web of Science, preprints, and grey literature for SARS-CoV-2 seroprevalence published between January 1, 2020 and May 20, 2022. The review protocol is registered with PROSPERO (CRD42020183634). We included general population cross-sectional and cohort studies meeting an assay quality threshold (90% sensitivity, 97% specificity; exceptions for humanitarian settings). We excluded studies with an unclear or closed population sample frame. Eligible studies—those aligned with the WHO Unity protocol—were extracted and critically appraised in duplicate, with risk of bias evaluated using a modified Joanna Briggs Institute checklist. We meta-analyzed seroprevalence by country and month, pooling to estimate regional and global seroprevalence over time; compared seroprevalence from infection to confirmed cases to estimate underascertainment; meta-analyzed differences in seroprevalence between demographic subgroups such as age and sex; and identified national factors associated with seroprevalence using meta-regression. We identified 513 full texts reporting 965 distinct seroprevalence studies (41% low- and middle-income countries [LMICs]) sampling 5,346,069 participants between January 2020 and April 2022, including 459 low/moderate risk of bias studies with national/subnational scope in further analysis. By September 2021, global SARS-CoV-2 seroprevalence from infection or vaccination was 59.2%, 95% CI [56.1% to 62.2%]. Overall seroprevalence rose steeply in 2021 due to infection in some regions (e.g., 26.6% [24.6 to 28.8] to 86.7% [84.6% to 88.5%] in Africa in December 2021) and vaccination and infection in others (e.g., 9.6% [8.3% to 11.0%] in June 2020 to 95.9% [92.6% to 97.8%] in December 2021, in European high-income countries [HICs]). After the emergence of Omicron in March 2022, infection-induced seroprevalence rose to 47.9% [41.0% to 54.9%] in Europe HIC and 33.7% [31.6% to 36.0%] in Americas HIC. In 2021 Quarter Three (July to September), median seroprevalence to cumulative incidence ratios ranged from around 2:1 in the Americas and Europe HICs to over 100:1 in Africa (LMICs). Children 0 to 9 years and adults 60+ were at lower risk of seropositivity than adults 20 to 29 (p < 0.001 and p = 0.005, respectively). In a multivariable model using prevaccination data, stringent public health and social measures were associated with lower seroprevalence (p = 0.02). The main limitations of our methodology include that some estimates were driven by certain countries or populations being overrepresented. Conclusions In this study, we observed that global seroprevalence has risen considerably over time and with regional variation; however, over one-third of the global population are seronegative to the SARS-CoV-2 virus. Our estimates of infections based on seroprevalence far exceed reported Coronavirus Disease 2019 (COVID-19) cases. Quality and standardized seroprevalence studies are essential to inform COVID-19 response, particularly in resource-limited regions.en_US
dc.description.sponsorshipThis work was supported by WHO (WHO COVID-19 Solidarity Response Fund, to IB; German Federal Ministry of Health COVID-19 Research and Development Fund, to IB; World Health Organisation funding, to RKA), the Public Health Agency of Canada (Canada's COVID-19 Immunity Task Force through the Public Health Agency of Canada, to RKA), the Canadian Medical Association (Joule Innovation Fund, to RKA), and the Robert Koch Institute (funding to RKA)en_US
dc.identifier.citationBergeri, I., Whelan, M.G., Ware, H., Subissi, L., Nardone, A., Lewis, H.C., Li, Z., Ma, X., Valenciano, M., Cheng, B. and Al Ariqi, L., 2022. Global SARS-CoV-2 seroprevalence from January 2020 to April 2022: A systematic review and meta-analysis of standardized population-based studies. PLoS medicine, 19(11), p.e1004107.en_US
dc.identifier.urihttps://uilspace.unilorin.edu.ng/handle/20.500.12484/11387
dc.language.isoenen_US
dc.publisherPLOS Medicineen_US
dc.relation.ispartofseries19 (11);p.e1004107
dc.subjectSARS CoV-2en_US
dc.subjectGlobal Seroprevalenceen_US
dc.subjectUNITY Protocolen_US
dc.titleGlobal SARS-CoV-2 seroprevalence: a systematic review and meta-analysis of standardized population-based studies from Jan 2020-May 2022en_US
dc.typeArticleen_US

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
journal.pmed.1004107.pdf
Size:
2.22 MB
Format:
Adobe Portable Document Format
Description:
Main article
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections